Abliva AB Publishes 2022 Annual Report

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the English version of the Annual report for 2022 is now available on the company’s website, www.abliva.com.

The Annual report is also attached below.